Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its second quarter 2020 financial results on August 4, 2020. A conference call is scheduled for 8:30 a.m. ET the same day, allowing investors to discuss the results and company updates. The company is known for its innovation in pharmaceutical development, particularly its lead compound, XPOVIO®, which has FDA approval for treating multiple myeloma and diffuse large B-cell lymphoma. Investors can access the live audio webcast through Karyopharm's [Investor section](http://investors.karyopharm.com/events-presentations).
- Karyopharm's lead drug XPOVIO® has received accelerated FDA approval for multiple myeloma and was recently approved for diffuse large B-cell lymphoma.
- Karyopharm has investigational programs in various stages of clinical development for potential treatments.
- None.
NEWTON, Mass., July 28, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, August 4, 2020, to discuss the financial results and other company updates.
To access the conference call, please dial (877) 870-4263 (local) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
View original content:http://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2020-financial-results-on-august-4-2020-301100550.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will Karyopharm report its second quarter 2020 financial results?
What time is the Karyopharm conference call regarding the financial results?
How can investors access Karyopharm's conference call?
What are Karyopharm's key products?
Is Karyopharm developing any other drugs?
